Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part I

被引:35
作者
Sajatovic, Martha [1 ,2 ]
Ross, Ruth [3 ]
Legacy, Susan N. [4 ]
Correll, Christoph U. [5 ,6 ]
Kane, John M. [5 ,6 ]
DiBiasi, Faith [7 ]
Fitzgerald, Heather [8 ]
Byerly, Matthew [9 ]
机构
[1] Univ Hosp Cleveland, Dept Psychiat, Med Ctr, 10524 Euclid Ave, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Dept Psychiat & Neurol, Cleveland, OH USA
[3] Ross Editorial, Port Townsend, WA USA
[4] Otsuka Pharmaceut Dev & Commercializat Inc, US Med Affairs Neurosci, Princeton, NJ USA
[5] Zucker Hillside Hosp, Psychiat, Glen Oaks, NY USA
[6] Donald & Barbara Zucker Sch Med Hofstra Northwell, Psychiat, Glen Oaks, NY USA
[7] Otsuka Pharmaceut Dev & Commercializat Inc, Sci Commun, Rockville, MD USA
[8] Lundbeck LLC, Med Affairs, Deerfield, IL USA
[9] Montana State Univ, Cell Biol & Neurosci Ctr, Mental Hlth Res & Recovery, Bozeman, MT 59717 USA
关键词
expert consensus; schizophrenia; schizoaffective disorder; bipolar disorder; long-acting injectable antipsychotics; BIPOLAR DISORDER; PSYCHOTIC DISORDERS; ORAL RISPERIDONE; SCHIZOPHRENIA; MEDICATION; ADHERENCE; ATTITUDES; RECOMMENDATIONS; PSYCHIATRISTS; NONADHERENCE;
D O I
10.2147/NDT.S167394
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess expert consensus on barriers and facilitators for long-acting injectable antipsychotic (LAI) use and provide clinical recommendations on issues where clinical evidence is lacking, including identifying appropriate clinical situations for LAI use. Methods: A 50-question survey comprising 916 response options was distributed to 42 research experts and high prescribers with extensive LAI experience. Respondents rated options on relative appropriateness/importance using a 9-point scale. Consensus was determined using chi-square test of score distributions. Mean (standard deviation) ratings were calculated. Responses to 29 questions (577 options) relating to appropriate patients and clinical scenarios for LAI use are reported. Results: Recommendations aligned with research on risk factors for nonadherence and poor outcomes for patients with schizophrenia/schizoaffective or bipolar disorder. Findings suggested, contrary to general practice patterns, that LAI use may be appropriate earlier in the disease course and in younger patients. Results for bipolar disorder were similar to those for schizophrenia but with less consensus. Numerous facilitators of LAI prescribing were considered important, particularly that LAIs may reduce relapses and improve outcomes. Conclusion: Findings support wider use of LAIs in patients with schizophrenia/schizoaffective and bipolar disorders beyond the setting of poor adherence and earlier use in the disease course.
引用
收藏
页码:1463 / 1474
页数:12
相关论文
共 47 条
[1]   A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia [J].
Alphs, Larry ;
Mao, Lian ;
Starr, H. Lynn ;
Benson, Carmela .
SCHIZOPHRENIA RESEARCH, 2016, 170 (2-3) :259-264
[2]   Antipsychotic long-acting injections: prescribing practice in the UK [J].
Barnes, Thomas R. E. ;
Shingleton-Smith, Amber ;
Paton, Carol .
BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 :S37-S42
[3]   Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia [J].
Bartzokis, George ;
Lu, Po H. ;
Raven, Erika P. ;
Amar, Chetan P. ;
Detore, Nicole R. ;
Couvrette, Alexander J. ;
Mintz, Jim ;
Ventura, Joseph ;
Casaus, Laurie R. ;
Luo, John S. ;
Subotnik, Kenneth L. ;
Nuechterlein, Keith H. .
SCHIZOPHRENIA RESEARCH, 2012, 140 (1-3) :122-128
[4]   Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory [J].
Bartzokis, George ;
Lu, Po H. ;
Amar, Chetan P. ;
Raven, Erika P. ;
Detore, Nicole R. ;
Altshuler, Lori L. ;
Mintz, Jim ;
Ventura, Joseph ;
Casaus, Laurie R. ;
Luo, John S. ;
Subotnik, Kenneth L. ;
Nuechterlein, Keith H. .
SCHIZOPHRENIA RESEARCH, 2011, 132 (01) :35-41
[5]   The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal [J].
Brissos, Sofia ;
Ruiz-Veguilla, Miguel ;
Taylor, David ;
Balanza-Martinez, Vicent .
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2014, 4 (05) :198-219
[6]  
Brook R H, 1986, Int J Technol Assess Health Care, V2, P53
[7]   Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia [J].
Byerly, Matthew J. ;
Thompson, Ann ;
Carmody, Thomas ;
Bugno, Rhiannon ;
Erwin, Thomas ;
Kashner, Michael ;
Rush, A. John .
PSYCHIATRIC SERVICES, 2007, 58 (06) :844-847
[8]  
Carbon M, 2014, DIALOGUES CLIN NEURO, V16, P505
[9]   A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder [J].
Chou, Yuan Hwa ;
Chu, Po-Chung ;
Wu, Szu-Wei ;
Lee, Jen-Chin ;
Lee, Yi-Hsuan ;
Sun, I-Wen ;
Chang, Chen-Lin ;
Huang, Chien-Liang ;
Liu, I-Chao ;
Tsai, Chia-Fen ;
Yen, Yung-Chieh .
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2015, 13 (02) :121-128
[10]   The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence [J].
Correll, Christoph U. ;
Citrome, Leslie ;
Haddad, Peter M. ;
Lauriello, John ;
Olfson, Mark ;
Calloway, Stephen M. ;
Kane, John M. .
JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 :3-+